157 related articles for article (PubMed ID: 31567943)
1. Effect of physical fitness on colorectal tumor development in patients with familial adenomatous polyposis.
Nakamura T; Ishikawa H; Sakai T; Ayabe M; Wakabayashi K; Mutoh M; Matsuura N
Medicine (Baltimore); 2019 Sep; 98(38):e17076. PubMed ID: 31567943
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
3. Colorectal Cancer in Individuals With Familial Adenomatous Polyposis, Based on Analysis of the Danish Polyposis Registry.
Karstensen JG; Burisch J; Pommergaard HC; Aalling L; Højen H; Jespersen N; Schmidt PN; Bülow S
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2294-2300.e1. PubMed ID: 30743005
[TBL] [Abstract][Full Text] [Related]
4. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.
Ishikawa H; Wakabayashi K; Suzuki S; Mutoh M; Hirata K; Nakamura T; Takeyama I; Kawano A; Gondo N; Abe T; Tokudome S; Goto C; Matsuura N; Sakai T
Cancer Med; 2013 Feb; 2(1):50-6. PubMed ID: 24133627
[TBL] [Abstract][Full Text] [Related]
5. Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool.
Lynch PM; Morris JS; Ross WA; Rodriguez-Bigas MA; Posadas J; Khalaf R; Weber DM; Sepeda VO; Levin B; Shureiqi I
Gastrointest Endosc; 2013 Mar; 77(3):455-63. PubMed ID: 23332604
[TBL] [Abstract][Full Text] [Related]
6. Two subtypes of colorectal tumor with distinct molecular features in familial adenomatous polyposis.
Takane K; Matsusaka K; Ota S; Fukuyo M; Yue Y; Nishimura M; Sakai E; Matsushita K; Miyauchi H; Aburatani H; Nakatani Y; Takayama T; Matsubara H; Akagi K; Kaneda A
Oncotarget; 2016 Dec; 7(51):84003-84016. PubMed ID: 27563825
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the timing of colorectal surgery in patients with familial adenomatous polyposis in clinical practice.
Vasen HFA; Ghorbanoghli Z; de Ruijter B; Trinidad RA; Langers AMJ; Peeters KCMJ; Bonsing BA; Hardwick JCH
Scand J Gastroenterol; 2019 Jun; 54(6):733-739. PubMed ID: 31401889
[No Abstract] [Full Text] [Related]
8. Association between the age and the development of colorectal cancer in patients with familial adenomatous polyposis: a multi-institutional study.
Kobayashi H; Ishida H; Ueno H; Hinoi T; Inoue Y; Ishida F; Kanemitsu Y; Konishi T; Yamaguchi T; Tomita N; Matsubara N; Watanabe T; Sugihara K
Surg Today; 2017 Apr; 47(4):470-475. PubMed ID: 27506752
[TBL] [Abstract][Full Text] [Related]
9. Survival of familial adenomatous polyposis coexistence colorectal cancer in Iran.
Mirinezhad SK; Moaddab SY; Bonyadi MJ; Shirmohammadi M; Eftekharsadat AT; Somi MH
J Cancer Res Ther; 2019; 15(1):87-91. PubMed ID: 30880760
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis.
Cruz-Correa M; Hylind LM; Marrero JH; Zahurak ML; Murray-Stewart T; Casero RA; Montgomery EA; Iacobuzio-Donahue C; Brosens LA; Offerhaus GJ; Umar A; Rodriguez LM; Giardiello FM
Gastroenterology; 2018 Sep; 155(3):668-673. PubMed ID: 29802852
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
12. Estrogen Receptor β as a Prognostic Marker of Tumor Progression in Colorectal Cancer with Familial Adenomatous Polyposis and Sporadic Polyps.
Stevanato Filho PR; Aguiar Júnior S; Begnami MD; Ferreira FO; Nakagawa WT; Spencer RMSB; Bezerra TS; Boggiss PE; Lopes A
Pathol Oncol Res; 2018 Jul; 24(3):533-540. PubMed ID: 28681123
[TBL] [Abstract][Full Text] [Related]
13. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
14. Ovarian metastases of colorectal and duodenal cancer in familial adenomatous polyposis.
Crobach S; van Wezel T; Vasen HF; Morreau H
Fam Cancer; 2012 Dec; 11(4):671-3. PubMed ID: 22941256
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
[TBL] [Abstract][Full Text] [Related]
16. A novel pathogenic splice acceptor site germline mutation in intron 14 of the APC gene in a Chinese family with familial adenomatous polyposis.
Wang D; Liang S; Zhang Z; Zhao G; Hu Y; Liang S; Zhang X; Banerjee S
Oncotarget; 2017 Mar; 8(13):21327-21335. PubMed ID: 28423518
[TBL] [Abstract][Full Text] [Related]
17. Resorting the function of the colorectal cancer gatekeeper adenomatous polyposis coli.
Kariv R; Caspi M; Fliss-Isakov N; Shorer Y; Shor Y; Rosner G; Brazowski E; Beer G; Cohen S; Rosin-Arbesfeld R
Int J Cancer; 2020 Feb; 146(4):1064-1074. PubMed ID: 31283021
[TBL] [Abstract][Full Text] [Related]
18. Regular endoscopic surveillance and polypectomy is effective in managing rectal adenoma progression following colectomy and ileorectal anastomosis in patients with familial adenomatous polyposis.
Anele CC; Xiang J; Martin I; Hawkins M; Man R; Clark SK; Faiz OD; Latchford A
Colorectal Dis; 2022 Mar; 24(3):277-283. PubMed ID: 34741380
[TBL] [Abstract][Full Text] [Related]
19. Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients.
Sample DC; Samadder NJ; Pappas LM; Boucher KM; Samowitz WS; Berry T; Westover M; Nathan D; Kanth P; Byrne KR; Burt RW; Neklason DW
BMC Gastroenterol; 2018 Jul; 18(1):115. PubMed ID: 30012100
[TBL] [Abstract][Full Text] [Related]
20. Management of familial adenomatous polyposis and MUTYH-associated polyposis; new insights.
Aelvoet AS; Buttitta F; Ricciardiello L; Dekker E
Best Pract Res Clin Gastroenterol; 2022; 58-59():101793. PubMed ID: 35988966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
